Why Quotient Limited (QTNT) jumped 29% on 09/12/17?

Quotient Limited (QTNT) jumped 29% as a result of Bullish news signal: Quotient Limited , a commercial-stage diagnostics company, today reported progress on performance evaluation studies for MosaiQ.

“Our latest performance evaluation results represent a key final step prior to commencing our verification and validation studies, allowing us to reaffirm our goal of completing planned field trials in Europe for MosaiQ during the second half of this year,” said Paul Cowan, Chairman and Chief Executive Officer of Quotient.

Assay Performance

Results of internal performance evaluation studies for the MosaiQ IH Microarray (the initial blood grouping microarray) and the MosaiQ SDS Microarray (the initial disease screening microarray) indicate that MosaiQ achieved the required targeted performance compared with predicate technologies. The performance evaluation data were derived using microarrays manufactured in Quotient’s validated, high-volume manufacturing facility and run on field trial-ready instruments. Final internal verification and validation studies for the MosaiQ IH Microarray and MosaiQ SDS Microarray are the next step in preparation for European field trials later this year.

finviz dynamic chart for  qtnt

Regulatory and Commercial Milestones – For Next Twelve Months are Confirmed

  • European Field Trials – Quotient expects to complete European field trials during CY17
  • European Regulatory Approval – Upon the successful completion of European field trials Quotient expects to file promptly for European regulatory approval for MosaiQ
  • European Commercialization – Quotient has commenced the commercialization of MosaiQ in Europe, where it has already received invitations to participate in tenders to be awarded in the middle of CY18
  • U.S. Field Trials and subsequent Regulatory Filing will follow the successful completion of European field trials.

MosaiQ, Quotient’s next-generation platform is designed to deliver fast, comprehensive antigen typing, antibody detection, and disease screening results, using a single low volume sample in a high throughput automated format. MosaiQ represents a transformative and highly disruptive unified testing platform for transfusion diagnostics. Feasibility has also been demonstrated with respect to the detection of nucleic acids (DNA or RNA) using the MosaiQ platform. Through MosaiQ, Quotient expects to deliver substantial value to donor testing laboratories worldwide by providing affordable, routine comprehensive characterization and screening of blood products, on a single automated instrument platform designed to radically reduce labor costs and complexity associated with the existing practice.

GlobeNewswire 

Explanation:

Why Bullish? Quotient has commenced the commercialization of MosaiQ in Europe, where it has already received invitations to participate in tenders to be awarded in the middle of CY18.  The stock has been impacted by the bullish news and jumped by 29%. It is very common that these type of news (i.e. positive clinical trial progression) will impact the stock in a bullish manner. Therefore, we provide this stock a  short-term bullish signal

Latest price: 3.71

Entry level: 4.3

Exit level: 4.58

Stop level: 4.2

  Jordan Mizrahi

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Stock bullish and bearish news signals will make you better trader

Providing stock news signals and monitoring service based on big data and text analysis of bullish and bearish news such as new buyout deal, FDA announcement, clinical trial results, new product/service, a joint venture agreement, new orders, sales numbers, financial results, analyst recommendation etc… Therefore, by utilizing the power of bullish and bearish news signals into your investments, you will dramatically improve results on profits more than any other investment techniques. We are the only company that produces investment signals (i.e. stock recommendation including entry, exit and stop levels for each recommendation) based on stock’s bullish and bearish news.

We use in-house crawl software to aggregate more than 5,000 stock news from 100’s data sources each day and use big data to arrange the news to sectors such: technology, pharma, bio tech, energy, retail etc… and text analysis to analyze the data… You will be received signals including entry, exit and stop levels premarket and during the trading hours.

 

Why register for a First To Invest PRO monthly subscription?

  • You will get 10 daily bullish and bearish stock news signals that moves prices in the short and long term

  • You can ask for online news signals on interested stocks via live chat before and during trading hours

  • Save you time by reading and analyzing 5,000 stock news from more than 100’s of data sources for you

  • We believe in our ability to generate you profits. That’s why we offer monthly subscription with no commitment and with full money-back guarantee in your first quarter of subscription

 

What is First to invest Pro subscription and flexible plan?
First to invest provides stock news signals for short and long term investments for one flat monthly fee or you can choose our flexible plan which allows you to choose how many signals to purchase and to control the flow. We are the only company that produces investment signals (i.e. stock recommendation including entry, exit and stop levels for each recommendation) based on stock’s bullish and bearish news.

What’s included in our service?
You’ll receive 10 daily pre-market and intra-day bullish and bearish news signals that can impact the price in the short and long term. For signals examples please click here

Which stock markets First to invest cover?
First to invest covers the US stocks markets at this moment with an ambition to expand into EU, Singapore, Hong Kong and China markets.

How will First to invest signals help me invest more fast and accurately?
We use in-house crawl software to aggregate more than 5,000 stock news from 100’s data sources each day and use big data to arrange the news to sectors such: technology, pharma, bio tech, energy, retail etc… and text analysis to analyze the data… You will be received signals including entry, exit and stop levels premarket and during the trading hours.

When do the stock news signals get delivered?
Between 30-60 minutes before the market opens and during the trade until the closing time

How the stock news signals delivered?
With your subscription to First to invest Pro, you can choose to receive our signals by Email and / or WhatsApp.

How much does First to invest cost?
The price will be $76.5 per month for the monthly subscription with no commitment. You can use our flexible plan which allows you to choose how many signals do you want and to control the flow for just $1.5 per signal.

What payment methods are accepted by First to invest?
First to invest accepts all major credit cards (Visa, MasterCard, American Express, Discover and Diners Club), via PayPal. (You don’t need a PayPal account)

What is the refund policy for First to invest PRO subscription?
If you are in any way unsatisfied with First to invest Pro monthly subscription during the first quarter of your subscription, we’ll provide you with a full refund, no questions asked.

[powr-plan-comparison id=6c6f0869_1473077432]